Ankylosing Spondylitis Clinical Trials

Local doctors are looking for people with Ankylosing Spondylitis (AS) for a clinical research study of an investigational drug. AS is a type of inflammatory arthritis that mostly affects the spine.

Local doctors are looking for people with Ankylosing Spondylitis (AS) for a clinical research study of an investigational drug. AS is a type of inflammatory arthritis that mostly affects the spine.

24-Week trial comparing treatment with Study Medicine vs. placebo. Patient Inclusion Criteria: Age >/= 18 Diagnosis of definite AS Active AS Inadequate response to treatment. Patient Exclusion Criteria: Major Surgery within 8 weeks prior to screening Inflammatory Disease other than AS Treatment with Investigational Medication within 4 weeks Hepatitis B, ...

Randomized, Double-Blind, Parallel-Group, Multi-center study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with AS who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label tx w/secukinumab 150 mg (ASLeap)  

Study of the effect of secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar)  

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of The Efficacy And Safety Of tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).  

Spondyloarthritis covers a group of diseases with common clinical, genetic and radiographic characteristics. Ankylosing spondylitis (AS) is the most common of these, and is usually diagnosed in the presence of bilateral sacroiliitis by conventional x-ray, according to the modified New York criteria. Axial spondyloarthritis (Ax-SpA) mainly affects the axial skeleton ...

Study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

This is a multi-center, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of ENIA11 in patients with ankylosing spondylitis. The study period for each patient will be 27 weeks, during which the patient will undergo screening for up to 21 days, and followed by treatment of 24 ...

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that predominantly affects sacroiliac joints and spine. It is the prototype of spondyloarthritides (SpA) and one of the most common rheumatic diseases. Sacroiliitis is the earliest manifestation of disease and accompanying with spinal involvement cause inflammatory back pain (IBP). IBP usually ...